×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
STOK – stoke therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
STOK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
1/15
09:15 am
stok
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
Medium
Report
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
1/12
09:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
1/11
02:13 pm
stok
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
Medium
Report
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
1/11
02:00 pm
stok
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Medium
Report
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
1/6
04:01 pm
stok
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
08:33 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
1/5
08:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $36.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $36.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
07:34 am
stok
Form 8-K Stoke Therapeutics, Inc. For: Jan 11
Low
Report
Form 8-K Stoke Therapeutics, Inc. For: Jan 11
1/5
04:16 pm
stok
Form 4 Stoke Therapeutics, Inc. For: Dec 31 Filed by: LEVIN ARTHUR A
Medium
Report
Form 4 Stoke Therapeutics, Inc. For: Dec 31 Filed by: LEVIN ARTHUR A
1/2
03:57 pm
stok
Form 8-K Stoke Therapeutics, Inc. For: Dec 05
Low
Report
Form 8-K Stoke Therapeutics, Inc. For: Dec 05
12/10
04:24 pm
stok
Form 4 Stoke Therapeutics, Inc. For: Dec 08 Filed by: Kaye Edward M. MD
Medium
Report
Form 4 Stoke Therapeutics, Inc. For: Dec 08 Filed by: Kaye Edward M. MD
12/10
04:24 pm
stok
Form 4 Stoke Therapeutics, Inc. For: Dec 08 Filed by: Allan Jonathan
Medium
Report
Form 4 Stoke Therapeutics, Inc. For: Dec 08 Filed by: Allan Jonathan
12/8
04:40 pm
stok
Form 144 Stoke Therapeutics, Inc. Filed by: Kaye Edward M. MD
Medium
Report
Form 144 Stoke Therapeutics, Inc. Filed by: Kaye Edward M. MD
12/8
04:39 pm
stok
Form 144 Stoke Therapeutics, Inc. Filed by: Allan Jonathan
Medium
Report
Form 144 Stoke Therapeutics, Inc. Filed by: Allan Jonathan
12/5
08:51 pm
stok
Form 4 Stoke Therapeutics, Inc. For: Dec 03 Filed by: Ticho Barry
Medium
Report
Form 4 Stoke Therapeutics, Inc. For: Dec 03 Filed by: Ticho Barry
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/25
Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
9.1%
3/23 Form 10-K Stoke Therapeutics, Inc. For: Dec 31 8.8%
2/14 Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Cormorant Asset Management, LP 6.7%
10/2 Form 4 Stoke Therapeutics, Inc. For: Oct 01 Filed by: RTW INVESTMENTS, LP 6.6%
11/1 Form 4 Stoke Therapeutics, Inc. For: Oct 30 Filed by: WONG RODERICK 6.1%
9/30 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference 5.9%
8/14 Form 8-K Stoke Therapeutics, Inc. For: Aug 14 4.4%
4/15 Form 8-K Stoke Therapeutics, Inc. For: Apr 14 4.2%
8/1 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference 4.1%
11/25 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting 4.1%
3/23 Form 10-K Stoke Therapeutics, Inc. For: Dec 31 8.8%
2/14 Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Cormorant Asset Management, LP 6.7%
10/2 Form 4 Stoke Therapeutics, Inc. For: Oct 01 Filed by: RTW INVESTMENTS, LP 6.6%
11/1 Form 4 Stoke Therapeutics, Inc. For: Oct 30 Filed by: WONG RODERICK 6.1%
9/30 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference 5.9%
8/14 Form 8-K Stoke Therapeutics, Inc. For: Aug 14 4.4%
4/15 Form 8-K Stoke Therapeutics, Inc. For: Apr 14 4.2%
8/1 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference 4.1%
11/25 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting 4.1%
TOP News Decliners
3/23
Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates
-11.7%
2/24 Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference -9.5%
12/23 Stoke Therapeutics Added to NASDAQ Biotechnology Index -8.4%
11/12 Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at BTIG Research. They set a "buy" rating and a $46.00 price target on the stock. -8.0%
10/16 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources -7.3%
10/8 Why Shares of Stoke Therapeutics Plummeted in September [The Motley Fool] -7.1%
9/11 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes -6.6%
6/21 Form 4 Stoke Therapeutics, Inc. For: Jun 21 Filed by: ATP III GP, Ltd. -6.5%
12/7 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome -6.5%
9/18 Stoke Therapeutics (NASDAQ: STOK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.1%
2/24 Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference -9.5%
12/23 Stoke Therapeutics Added to NASDAQ Biotechnology Index -8.4%
11/12 Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at BTIG Research. They set a "buy" rating and a $46.00 price target on the stock. -8.0%
10/16 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources -7.3%
10/8 Why Shares of Stoke Therapeutics Plummeted in September [The Motley Fool] -7.1%
9/11 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes -6.6%
6/21 Form 4 Stoke Therapeutics, Inc. For: Jun 21 Filed by: ATP III GP, Ltd. -6.5%
12/7 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome -6.5%
9/18 Stoke Therapeutics (NASDAQ: STOK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: